Although local prostate cancer (PC) can be cured in most cases by radical p
rostatectomy, thera pies for metastatic and androgen-independent PC are lim
ited and rather unsatisfactory. Gene and immunotherapy based on progress in
molecular biology are novel treatment options especially for these PC stag
es.
In the field of passive immunotherapy, chimeric/recombinant antibodies and
derivatives thereof show promising results in early clinical trails (phase
I/II). Before treatment, a careful selection of patients who could profit f
rom this therapy is important (theranostics). Concerning active immunothera
py, administration of dendritic cells loaded with PC-specific tumor antigen
s seems to be an interesting therapy option.
Promising gene therapeutic approaches include antisense and suicide gene th
erapy. Antisense therapy studies revealed the advantage that even systemic
treatment does not lead to strong toxic side effects if the target gene is
not involved in important cell functions. Improvement of the gene therapy v
ectors and identification of new therapeutic genes for PC are essential pre
requisites for successful application in humans.
Present developments of alternative approaches show that future treatments
will be very patient specific.